Teva Pharmaceutical (TEVA) Stock Analysis

November 11, 2026

This is a peer-relative look at Teva Pharmaceutical (TEVA): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Teva Pharmaceutical (TEVA) trades as an ADR rather than ordinary local shares — read it with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile fields for Teva Pharmaceutical (TEVA)
Profile Item	TEVA
Name	Teva Pharmaceutical Industries Ltd. ADR
Country/Region	Israel
GICS Sector	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals
GICS Sub-Industry	Pharmaceuticals
Market Capitalization	49.72 billion USD
Currency	USD
Exchange	NYSE
Listing Date	February 16, 1982
Security Type	ADR

Price Performance

Cumulative Growth

TEVA

GSPC

Teva Pharmaceutical (TEVA) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Teva Pharmaceutical (TEVA) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Teva Pharmaceutical (TEVA) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Teva Pharmaceutical (TEVA) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: TEVA	Industry group median
Total Return (1Y)	79.58%	24.62%
Total Return (3Y, Annualized)	69.94%	20.37%
Total Return (5Y, Annualized)	35.86%	-4.02%

Risk Profile

Drawdown History

TEVA

GSPC

Teva Pharmaceutical (TEVA) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Teva Pharmaceutical (TEVA) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Teva Pharmaceutical (TEVA) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: TEVA	Industry group median
Volatility (1Y, Annualized)	33.95%	66.36%
Beta (5Y)	0.96	0.93
Max Drawdown (5Y)	-43.70%	-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. TEVA is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

Teva Pharmaceutical (TEVA) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: TEVA	Industry group median
Sharpe Ratio (1Y)	2.22	0.36
Sortino Ratio (1Y)	3.94	0.58

Profitability

ROE (TTM)

Teva Pharmaceutical (TEVA) posts ROE of 6.65%, in the upper peer quartile. That suggests the company earns more from each dollar of shareholders’ equity than most industry peers, a useful capital-efficiency signal.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.65%

Group distribution

Max: 109.18%
TEVA: 6.65%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Largest peers

LLY: 86.02%
NVS: 24.33%
AZN: 22.57%
JNJ: 20.02%
TEVA: 6.65%
MRK: 5.06%
ABBV: --

Where Teva Pharmaceutical (TEVA) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

Teva Pharmaceutical (TEVA) keeps 2.94% of revenue as net profit, roughly in line with the peer group’s normal net margin range. Its full cost stack is taking a typical share of sales for the industry.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.94%

Group distribution

Max: 18.05%
Q3: 4.78%
TEVA: 2.94%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Largest peers

LLY: 31.90%
AZN: 17.68%
NVS: 17.49%
JNJ: 16.20%
ABBV: 15.67%
MRK: 3.64%
TEVA: 2.94%

Where Teva Pharmaceutical (TEVA) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

Teva Pharmaceutical (TEVA) turns 27.40% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.40%

Group distribution

Max: 83.12%
TEVA: 27.40%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Largest peers

LLY: 53.66%
ABBV: 39.59%
MRK: 35.22%
NVS: 34.27%
AZN: 29.57%
TEVA: 27.40%
JNJ: 25.74%

Where Teva Pharmaceutical (TEVA) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

Teva Pharmaceutical (TEVA) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: TEVA	Industry group median
ROE (TTM)	6.65%	-26.66%
ROA (TTM)	5.35%	-12.50%
Net Margin (TTM)	2.94%	0.00%
Operating Margin (TTM)	27.40%	0.00%
Gross Margin (TTM)	53.51%	37.87%

Growth

Revenue Growth

Teva Pharmaceutical (TEVA) grew revenue 4.31%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

Teva Pharmaceutical (TEVA): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

No usable EPS growth is available for Teva Pharmaceutical (TEVA) this period, so the earnings-momentum read is skipped.

Teva Pharmaceutical (TEVA) doesn't report EPS Growth this period; the bars show the Pharmaceuticals, Biotechnology & Life Sciences industry-group medians on their own.

Growth Metrics

Teva Pharmaceutical (TEVA) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: TEVA	Industry group median
Revenue Growth (YoY)	4.31%	11.45%
Revenue Growth (3Y CAGR)	4.96%	9.94%
EPS Growth (YoY)	--	4.28%
EPS Growth (3Y CAGR)	--	4.17%

Financial Strength

Current Ratio (MRQ)

Teva Pharmaceutical (TEVA) has current ratio of 0.95, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.95

Group distribution

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TEVA: 0.95
Min: 0.10

Largest peers

LLY: 1.39
MRK: 1.35
JNJ: 1.02
AZN: 1.01
TEVA: 0.95
NVS: 0.88
ABBV: 0.87

Where Teva Pharmaceutical (TEVA) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

Teva Pharmaceutical (TEVA) has debt-to-equity ratio of 2.13, above the industry benchmark range. Debt sits unusually high against shareholders’ equity, leaving the balance sheet more exposed to rate, refinancing, or earnings shocks.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.13

Group distribution

TEVA: 2.13
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Largest peers

TEVA: 2.13
NVS: 1.29
LLY: 1.23
MRK: 1.20
AZN: 0.66
JNJ: 0.55
ABBV: --

Where Teva Pharmaceutical (TEVA) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

Teva Pharmaceutical (TEVA) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: TEVA	Industry group median
Current Ratio (MRQ)	0.95	5.52
Debt / Equity (MRQ)	2.13	0.15
Net Debt / EBITDA	2.93	1.08

Dividends

Dividend Yield (TTM)

Teva Pharmaceutical (TEVA) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

TEVA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

NVS: 2.88%
ABBV: 2.40%
MRK: 2.29%
JNJ: 1.94%
AZN: 1.73%
LLY: 0.49%
TEVA: 0.00%

Where Teva Pharmaceutical (TEVA) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

Teva Pharmaceutical (TEVA) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

TEVA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

MRK: 343.43%
ABBV: 117.35%
NVS: 90.46%
JNJ: 80.12%
AZN: 45.38%
LLY: 21.71%
TEVA: 0.00%

Where Teva Pharmaceutical (TEVA) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

Teva Pharmaceutical (TEVA) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: TEVA	Industry group median
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Teva Pharmaceutical (TEVA) trades at P/E ratio of 99.09, above the peer range for its industry. The market is paying unusually heavily for TTM earnings relative to comparable companies.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

99.09

Group distribution

TEVA: 99.09
Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Largest peers

MRK: 148.21
TEVA: 99.09
ABBV: 50.05
LLY: 43.95
JNJ: 41.92
NVS: 31.02
AZN: 26.37

Where Teva Pharmaceutical (TEVA) stands on P/E ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/S Ratio (TTM)

Teva Pharmaceutical (TEVA) trades at 2.89 on P/S ratio, in the lower sales-valuation quartile for its industry. That points to a cheaper revenue stream than most peers, with margin quality still doing the heavy lifting.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.89

Group distribution

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
TEVA: 2.89
Min: 0.01

Largest peers

LLY: 13.95
ABBV: 7.80
JNJ: 6.69
MRK: 5.37
NVS: 5.35
AZN: 4.63
TEVA: 2.89

Where Teva Pharmaceutical (TEVA) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

Teva Pharmaceutical (TEVA) trades at 6.23 on P/B ratio, roughly in line with the industry’s normal price-to-book range. Its balance sheet is not being priced at a clear discount or premium versus peers.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.23

Group distribution

Max: 13.53
Q3: 6.54
TEVA: 6.23
Median: 3.25
Q1: 1.69
Min: -5.59

Largest peers

LLY: 29.96
NVS: 8.25
JNJ: 8.16
MRK: 8.06
TEVA: 6.23
AZN: 5.59
ABBV: -112.34

Where Teva Pharmaceutical (TEVA) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

Teva Pharmaceutical (TEVA) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: TEVA	Industry group median
P/E Ratio (TTM)	99.09	26.69
P/S Ratio (TTM)	2.89	7.30
P/B Ratio (MRQ)	6.23	3.25
Free Cash Flow Yield (TTM)	3.00%	-1.66%